Tag Archives: Sanofi

November, 2015

  • 20 November

    AstraZeneca and Sanofi Agree to Exchange 210,000 Compounds

    Paris, France – November 20, 2015 – Sanofi and AstraZeneca today announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries. The exchange represents a novel, open innovation model of collaboration between two leading pharmaceutical companies. It will enhance the chemical diversity of the compound collections of …

  • 5 November

    Sanofi Enters Diabetes License Deal with Hanmi Pharmaceutical

    PARIS and SEOUL, South Korea, Nov. 5, 2015 /PRNewswire-USNewswire/ — Sanofi and Hanmi Pharmaceutical Co., Ltd. announced today a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments. Under the terms of the agreement, Hanmi will receive an upfront payment of €400 million and is eligible for up …

  • 3 November

    Sanofi and BioNTech Enter an Up to $1.58 Billion Immuno-Oncology Partnership

    PARIS and MAINZ, Germany, November 3, 2015 /PRNewswire via COMTEX/ — Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to …

July, 2015

  • 31 July

    FDA Approves Sanofi’s PCSK9 Drug Praluent

    PARIS and TARRYTOWN, N.Y., July 24, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as …

  • 8 July

    Sanofi to Pay $245 Million for Retrophin’s Rare Disease Priority Review Voucher

    SAN DIEGO–(BUSINESS WIRE)–Retrophin, Inc. (NASDAQ:RTRX) today announced the closing of the agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (EURONEXT: SAN and NYSE: SNY). Under the terms of the agreement, Retrophin has received a payment of $150 million, and will receive two additional payments of $47.5 …

June, 2015

  • 8 June

    Breakthrough Status Granted to Genzyme’s Rare Enzyme Replacement Drug

    Genzyme, a Sanofi company, recently announced that its investigational enzyme-replacement therapy was granted Breakthrough Therapy designation from US health regulators. The company said that the agency granted the status to its olipudase alfa for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick …

May, 2015

April, 2015